Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Imugene ( (AU:IMU) ) has shared an update.
Imugene Limited has notified the market of the issue of additional unquoted options under ASX code IMUAJ, each exercisable at $0.86 and expiring on 30 June 2028. A total of 2,872 options were issued across two tranches on 4 and 5 March 2026, as part of previously announced transactions and are not intended to be quoted on the ASX.
The new options expand Imugene’s pool of unquoted equity instruments used for financing or incentivising staff, directors, or partners, without immediately diluting existing shareholders through listed securities. This move reflects ongoing execution of the company’s capital management plans but does not alter its quoted share capital structure in the near term.
The most recent analyst rating on (AU:IMU) stock is a Sell with a A$0.22 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is an ASX-listed biotechnology company focused on developing cancer immunotherapies. The company issues options and other equity-linked securities as part of its capital management and incentive arrangements for stakeholders in the Australian market.
Average Trading Volume: 1,404,984
Technical Sentiment Signal: Sell
Current Market Cap: A$73.95M
For an in-depth examination of IMU stock, go to TipRanks’ Overview page.